CION Ameerpet
Pancreatic Cancer · Hereditary Risk & Genetics · Reviewed by CION Oncologists
PALB2 and pancreatic cancer — what the gene change really means
PALB2 is the gene that partners BRCA2 in repairing damaged DNA, and a fault in it raises the lifetime chance of pancreatic cancer. That is a raised risk, not a diagnosis — most carriers never develop the disease. This page explains what the result changes, for you and for your relatives.
- PALB2 partners BRCA2 — the two genes work on the same DNA-repair job, which is why they appear together.
- A raised risk, not a forecast — most people carrying a PALB2 change never develop pancreatic cancer.
- It matters most to your relatives — each first-degree relative has a one-in-two chance of carrying the same change.
- Surveillance is offered selectively — usually where a PALB2 result sits alongside pancreatic cancer in the family.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What PALB2 Is — and What a Change in It Actually Means
Most people who search for PALB2 pancreatic cancer are not idly curious. A laboratory report has landed — theirs, or a relative's — with a gene name on it that nobody in the family had heard of a fortnight ago, and the question underneath it is simple and urgent: what does this mean for me?
The name is the most useful thing about it. PALB2 stands for partner and localizer of BRCA2. The protein it makes does exactly that: it holds BRCA2 in the right place inside the cell nucleus so that broken strands of DNA can be repaired accurately. When one inherited copy of the PALB2 gene carries a fault, that repair machinery works less reliably over a lifetime, and cells that have picked up damage are a little more likely to survive and accumulate further faults. That is the entire mechanism. It is also why PALB2 keeps turning up in the same sentence as BRCA — the two are colleagues on one repair pathway, which is covered in more detail on our page about BRCA2 and BRCA1 in pancreatic cancer.
A change in the PALB2 gene raises the lifetime chance of several cancers — breast cancer most clearly, pancreatic cancer meaningfully, and ovarian cancer to a smaller degree. Raising a chance is not the same as causing an outcome. Most people who carry a PALB2 change will never develop pancreatic cancer, and the great majority of pancreatic cancer occurs in people with no inherited gene change at all. If you take one sentence away from this page, take that one.
What a PALB2 result does change is what can sensibly be offered. It gives your relatives something specific to test for rather than a vague worry. It can open the door to a structured surveillance programme where the family history supports it. And if cancer is ever diagnosed in someone carrying the change, the result is already on file when systemic treatment is planned. Who should be tested in the first place, and how the test is arranged, is set out on germline genetic testing for pancreatic cancer. For the disease itself — symptoms, tests, staging and treatment — start from our complete guide to pancreatic cancer. This page stays on the gene.
Did you know? NCCN guidelines recommend that germline genetic testing be offered to everyone diagnosed with pancreatic ductal adenocarcinoma, not only to those with a striking family history — and PALB2 sits on the standard gene panel used for that testing, alongside BRCA1, BRCA2, ATM, CDKN2A and the Lynch-syndrome genes. The same guidance, together with international consensus statements on pancreatic surveillance, supports considering a structured surveillance programme for people who carry a PALB2 change and also have pancreatic cancer in the family. That pairing is deliberate. For this particular gene, the family history is usually what tips the decision — which is why a counselling appointment asks about your relatives in far more detail than you expect before anyone starts talking about scans.
Reading the report
What a PALB2 Result Actually Changes
A gene result is a piece of information about probability. These are the six places where that information genuinely does something.
The mechanism
DNA repair, working less reliably
The PALB2 protein positions BRCA2 for accurate repair of broken DNA. A faulty copy makes that repair less dependable over decades — a slow drift, not a switch that flips.
The pancreas
A raised risk, not a forecast
The PALB2 gene is a recognised inherited contributor to pancreas cancer risk. It sits below the level of certainty and well above background chance — which is why it prompts a conversation rather than a panic.
The breast
The risk families usually hear about first
Most PALB2 changes are found during breast-cancer genetics, not pancreatic. Breast screening and risk-reducing options are handled by a breast service; the pancreatic side of the same result is what this page addresses.
Your relatives
A one-in-two chance, for each of them
The change is passed on in a dominant pattern, so each child, brother and sister of a carrier has a one-in-two chance of carrying it too. Testing them is far quicker once the exact family change is known.
Surveillance
It can open a monitoring pathway
Where a PALB2 result sits alongside pancreatic cancer in close blood relatives, guidance supports considering structured imaging surveillance. That is offered selectively, and it is not the same thing as screening the population.
If cancer is ever diagnosed
The result travels with you
A known germline result is taken into account when systemic treatment is planned, because the DNA-repair pathway a tumour arises through is relevant to how drug classes are chosen. That detail belongs on pancreatic cancer treatment in Hyderabad.
A prompt, not a diagnosis
When a PALB2 Result Changes What Happens Next
None of these means you have cancer. They are the situations where a specialist conversation leads to a different plan rather than simply to reassurance.
- A PALB2 change has been confirmed in you, and nobody has yet talked to you about what it means for the pancreas specifically rather than for the breast.
- A PALB2 change has been confirmed in a parent, brother, sister or child, and you have not been tested yourself. This is the single most useful appointment on this page — see germline genetic testing for pancreatic cancer.
- A PALB2 result sits alongside pancreatic cancer in a close blood relative. This is the combination where structured surveillance is most likely to be considered.
- Your family carries pancreatic, breast, ovarian or prostate cancer on the same side, and no gene has been identified yet. Counselling comes before any test, so you know in advance what a result would and would not mean.
- You have been told the result is a “variant of uncertain significance.” That is not a positive result and should not be treated as one. It needs explaining properly rather than acting on.
- You carry a change and want to know how it compares with the BRCA genes, which behave similarly but not identically — see BRCA2 and BRCA1 in pancreatic cancer.
What we will not do: treat a gene result as a diagnosis, or send a well person for scans that guidance does not support in order to settle an anxiety a proper conversation can settle. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Gene Result Only Helps If Someone Acts On It
One conversation turns a laboratory report into a plan — for you, and for the relatives it also concerns.
What actually happens
What Happens When You Bring a PALB2 Result to Us
-
A free 45-minute consultation, with the report in front of us
Bring the laboratory report itself, not a summary of it. We read the exact variant, check whether it is genuinely pathogenic or a variant of uncertain significance, and draw out the family history properly — both sides, several generations, every cancer and roughly how old each relative was.
In-house at CION -
Genetic counselling, before anything is decided
Counselling is where a gene name becomes a plan. It covers what the change does, what it does not do, who else in the family it affects, and what you would do with each possible result. Where testing has not happened yet, counselling comes before the test rather than after it — the pathway is set out on germline genetic testing for pancreatic cancer.
In-house at CION -
An honest answer on surveillance
If your profile fits the guidance, we explain what a surveillance programme involves and arrange the imaging. If it does not, we say so plainly rather than starting scans that will generate findings nobody knows how to act on. Pancreatic-protocol CT, MRI with MRCP, CA 19-9 and routine bloods are ordered and reported by CION.
In-house at CION -
Endoscopic ultrasound, arranged with partner centres
Most pancreatic surveillance protocols alternate MRI with endoscopic ultrasound. EUS, EUS-guided biopsy, ERCP and stenting are not in-house CION services — they are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partner centres and may be billed there. We arrange them and track the results; we do not perform them.
Coordinated with specialist partner centres -
Cascade testing for the relatives who want it
Once the exact family change is known, testing a relative is a targeted test rather than a full panel. Some family members will want it and some will not, and both are legitimate. If a diagnosis is ever made in anyone, the pathway from that point is set out on pancreatic cancer treatment in Hyderabad, and all pancreatic surgery is coordinated with our HPB partner centres.
In-house at CION, with coordinated surgery
There is no population screening test for pancreatic cancer, and CA 19-9 is not one — we will not sell you either. What we can do is tell you honestly whether your PALB2 result puts you in the group guidance says to watch. Book a free consultation or call 1800 202 8726.
The honest limits
What Surveillance Can and Cannot Do for a PALB2 Carrier
Inherited-risk surveillance is one of the few settings in pancreatic cancer where genuine early detection is a realistic goal, and that is worth saying clearly. It is also not a guarantee, and the people who cope best with it are the ones who understood the limits before they started. A surveillance programme is periodic imaging of the pancreas, generally alternating MRI with MRCP and endoscopic ultrasound, run through a specialist service and continued for years. It usually begins in middle age, or earlier where someone in the family was diagnosed young.
What it can do is find a small change at a point where something can still be done about it, and build a baseline so that next year's scan is compared with your own pancreas rather than with a textbook. What it cannot do is promise that nothing will ever be missed. Scans also turn up incidental things — small cysts in particular are common and usually harmless — and a surveillance programme has to be run by people who know which of those findings to act on and which to simply record. That judgement is precisely why surveillance belongs inside a structured programme rather than in an annual scan booked privately.
A PALB2 result is also not the whole of your risk. Smoking, long-standing chronic pancreatitis and substantial excess body weight all still matter, and they matter more, not less, in someone already carrying an inherited change. Stopping smoking remains the single most useful thing any carrier can do, and it is worth more than any scan on the calendar.
Finally, a word for the relatives who test negative for a change already known in the family. That is a genuinely reassuring result for that specific change, and it means your own children cannot inherit it through you. It does not make you immune to pancreatic cancer, because most of the disease has nothing to do with inherited genes — so a persistent new symptom, and painless yellowing of the eyes or skin above all, still deserves checking on its own merits and in the same week. The wider picture is covered in our complete guide to pancreatic cancer, and the closely related gene story on BRCA2 and BRCA1 in pancreatic cancer.
Take the next step
Inherited Risk Is One of the Few Things You Can Know in Advance
Understanding what a PALB2 result does and does not mean makes every decision after it easier. We walk this journey with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
PALB2 and pancreatic cancer - your questions answered
What does a PALB2 gene change actually do?
PALB2 stands for partner and localizer of BRCA2. The protein it makes holds BRCA2 in the right position inside the cell nucleus so that broken strands of DNA can be repaired accurately. Everybody inherits two copies of the gene. When one of those copies carries a fault, that repair process works less reliably over a lifetime, and cells that have picked up damage are slightly more likely to survive and go on accumulating further faults. That is the whole mechanism, and it plays out slowly, over decades, rather than as a single event. It is also why PALB2 and the BRCA genes are so often mentioned in the same breath: they are colleagues on the same repair pathway rather than unrelated genes that happen to raise similar risks.
If I carry a PALB2 change, does that mean I will get pancreatic cancer?
No. Carrying a PALB2 change raises the chance of developing certain cancers over a lifetime; it does not mean the disease is coming. Most people who carry a PALB2 change never develop pancreatic cancer, and the great majority of pancreatic cancer occurs in people with no inherited gene change at all. What the result does is move you into a group where a specialist conversation is worthwhile, where relatives have something specific to test for, and where structured monitoring may be considered if the family history supports it. Treat it as information that changes what can sensibly be offered to you, not as a diagnosis and not as a countdown. If anyone has described your result to you as a verdict, that description was wrong and is worth correcting.
Is PALB2 the same as BRCA2?
They are not the same gene, but they do the same job. PALB2 positions BRCA2 so that accurate DNA repair can happen, which is why a fault in either gene produces a broadly similar problem inside the cell. In practice the two are tested on the same panel and counselled in much the same way, and both are recognised inherited contributors to pancreatic cancer risk as well as to breast cancer risk. The differences sit in the detail: the size of the risk attached to each cancer type differs between the genes, and some of the risk-reducing and surveillance options that apply to BRCA carriers are weighed differently for PALB2. Our page on BRCA and pancreatic cancer works through that comparison properly.
Should my children, brothers and sisters be tested?
It is worth them knowing the option exists, and worth them making the decision themselves rather than having it made for them. A PALB2 change is passed on in a dominant pattern, so each first-degree relative has a one-in-two chance of carrying the same change. Once the exact variant in your family is known, testing a relative is a targeted, straightforward test rather than a full gene panel. The right sequence is counselling first, then testing, because the useful question is not simply whether they carry it but what each of them would actually do with the answer. Some relatives will want to know and some will not, and both positions are reasonable. Nobody should be pushed into a test they have not decided they want.
What does pancreatic surveillance for a PALB2 carrier actually involve?
It is periodic imaging of the pancreas run through a specialist service, generally alternating MRI with MRCP and endoscopic ultrasound, and continued over years rather than done once. It usually begins in middle age, or earlier where someone in the family was diagnosed young. Guidance supports considering surveillance for PALB2 carriers particularly where pancreatic cancer is also present in close blood relatives, so it is offered selectively rather than to everyone carrying a change. At CION the MRI, CT, CA 19-9 and routine bloods are ordered and reported in-house. Endoscopic ultrasound and any biopsy are coordinated with specialist gastroenterology and endoscopy partner centres and may be billed there. Surveillance is not the same as screening the general population, which is not recommended anywhere.
What does CION do for someone with a PALB2 result, and what happens at the first visit?
The first appointment is a free 45-minute consultation, and it is a conversation rather than a queue. Bring the laboratory report itself. We read the exact variant, confirm whether it is pathogenic or a variant of uncertain significance, and take the family history in detail across both sides. Genetic counselling, risk assessment, cascade-testing advice for relatives, pancreatic-protocol CT, MRI with MRCP, CA 19-9 and bloods, medical and radiation oncology, nutrition and enzyme support, pain relief, psycho-oncology and survivorship care are all delivered by CION across our 35+ centres. Endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, PET-CT and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partner centres and may be billed there. You leave with a written plan, whatever the report says.
Medical disclaimer: This page explains what a germline PALB2 gene change means for pancreatic cancer risk, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma and on genetic and familial high-risk assessment. It is general information and not a risk calculation or a report interpretation for any individual; your own result, family history and surveillance plan must be discussed with a doctor who has seen them. Genetic counselling, family-history and risk assessment, cascade-testing advice, pancreatic-protocol CT, MRI/MRCP, CA 19-9 and routine bloods, medical and radiation oncology, nutrition and enzyme (PERT) support, pain, psycho-oncology and survivorship care are delivered by CION. Endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, PRRT and all pancreatic surgery are coordinated with specialist HPB, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there.